INO-5401 + INO-9012
Phase 1Active 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRCA1/2 Mutation
Conditions
BRCA1/2 Mutation
Trial Timeline
Apr 20, 2021 → Mar 1, 2027
NCT ID
NCT04367675About INO-5401 + INO-9012
INO-5401 + INO-9012 is a phase 1 stage product being developed by Inovio Pharmaceuticals for BRCA1/2 Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT04367675. Target conditions include BRCA1/2 Mutation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04367675 | Phase 1 | Active |
Competing Products
1 competing product in BRCA1/2 Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olaparib + Olaparib + Placebo + Placebo | AstraZeneca | Phase 3 | 77 |